Evidence map›Paper›PMID 40563542›Full record

ArticleBiomolecules2025

Enhanced Therapeutic Efficacy of Omeprazole Nanosuspension in Ethanol-Induced Gastric Ulcer: A Focus on Oxidative Stress and Inflammatory Pathways.

Mody Albalawi, Sahar Khateeb

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Combined Omeprazole andInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Protective effect of magnesium on indomethacin-induced gastric ulcer in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mody AlbalawiDepartment of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0009-0009-4955-5705
Sahar KhateebDepartment of Biochemistry, Faculty of Science, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0000-0002-1524-7247

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric ulcer is a concerning condition that affects numerous individuals globally. Omeprazole (OMP), a well-known drug for treating stomach ulcers, has been associated with several adverse effects and limited solubility. The study aimed to create an omeprazole nanosuspension (OMP-NS) with improved solubility and bioavailability. Additionally, the study investigated the potential therapeutic effects of OMP-NS on ethanol-induced gastric injury in rats, comparing it to traditional OMP therapy to identify novel therapeutic alternatives. The characterization of the OMP-NS was assessed using DLS, TEM, XRD, FTIR, UV spectrophotometric analysis, in vitro release studies, and entrapment efficiency (EE) assays. A total of 24 male Wistar albino rats (weighing 150-200 g, aged 8-10 weeks) were randomly divided into four groups (six rats/group). Gastric injury was induced using absolute ethanol (5 mL/kg), followed by oral administration of either OMP or OMP-NS (20 mg/kg) for 7 days. Data were analyzed using one-way ANOVA accompanied by the Bonferroni post hoc test or the Kruskal-Wallis test, based on data distribution, with significance set at

Indexed as

Anti-Ulcer AgentsEthanolNanoparticlesOmeprazoleOxidative StressStomach UlcerAnimalsInflammationMaleRatsRats, WistarSuspensionsAnti-Ulcer AgentsEthanolOmeprazoleSuspensionsbioavailabilitycytokinesethanolgastric ulcerinflammationnanosuspensionsNrf2/PPAR-γ/SIRT1 pathwayomeprazoleROS

Identifiers

PMID40563542
PMCPMC12190574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.